Litigation Details for Chiesi U.S.A., Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
✉ Email this page to a colleague
Chiesi U.S.A., Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
Docket | ⤷ Sign Up | Date Filed | 2017-12-06 |
Court | District Court, D. Delaware | Date Terminated | 2019-01-13 |
Cause | 35:271 Patent Infringement | Assigned To | William C. Bryson |
Jury Demand | None | Referred To | Mary Pat Thynge |
Parties | CHIESI U.S.A., INC. | ||
Patents | 6,987,094; 7,696,178; 7,939,502 | ||
Attorneys | Frederick L. Cottrell , III | ||
Firms | Shaw Keller LLP | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Chiesi U.S.A., Inc. v. Teva Pharmaceuticals USA, Inc.
Details for Chiesi U.S.A., Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2017-12-06 | 1 | United States Patent Nos. 6,987,094 (“the ’094 patent”), 7,696,178 (“the ’178 patent”), and 7,939,502… This is a civil action for patent infringement arising under the patent laws of the United States, …’502 patent”), attached hereto as Exhibits A, B, and C, respectively (collectively, “the patents-in-suit…Farmaceutici S.p.A. owns the ’094 patent. 28. The ’178 patent, entitled “Optimized Formulation…Farmaceutici S.p.A. owns the ’178 patent. 29. The ’502 patent, entitled “Optimized Formulation | External link to document | |
2017-12-06 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,987,094; 7,696,178; 7,939,502…2017 14 January 2019 1:17-cv-01772 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
2019-01-22 | 95 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,987,094; 7,696,178; 7,939,502…2017 14 January 2019 1:17-cv-01772 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |